Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19584865.
- Also identified by DOI 10.1038/nm.1993 and PMC identifier 2772128.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80- and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.
Medical subject headings
- Graft Survival
- Kidney Transplantation
- Recombinant Fusion Proteins